Roivant Sciences (ROIV) EBT (2020 - 2025)
Roivant Sciences (ROIV) reported EBT of -$290.4 million for Q4 2025, down 23.82% on a YoY basis from -$381.2 million in Q4 2024, and down 82.57% quarter-over-quarter from -$159.0 million in Q3 2025.
Roivant Sciences (ROIV) EBT (2020 - 2025) Analysis & Trends
Roivant Sciences has reported EBT for 6 years, with the latest figure at -$290.4 million in Q4 2025.
- For the quarter ending Q4 2025, EBT fell 23.82% year-over-year to -$290.4 million; the trailing twelve-month figure through Dec 2025 stood at -$953.2 million (down 120.39% YoY), and the FY2026 full-year result was -$264.6 million, up 61.18% from the prior year.
- EBT for Q4 2025 stood at -$290.4 million, down from -$159.0 million in the prior quarter.
- The five-year high for EBT was $5.2 billion in Q4 2023, with the low at -$382.1 million in Q4 2022.
- Historically, EBT has averaged $114.1 million across 5 years, with a median of -$241.4 million in 2023.
- Annual changes were most pronounced in 2021 — EBT tumbled 1394.75% — and 2023, when it jumped 1448.82%.
- Roivant Sciences' EBT stood at -$306.0 million in 2021, then decreased by 24.84% to -$382.1 million in 2022, then jumped by 1448.82% to $5.2 billion in 2023, then sank by 104.55% to -$234.5 million in 2024, then fell by 23.82% to -$290.4 million in 2025.
- The last three EBT figures came in at -$290.4 million (Q4 2025), -$159.0 million (Q3 2025), and -$269.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -290.37 Mn |
| Sep 30, 2025 | -159.04 Mn |
| Jun 30, 2025 | -269.26 Mn |
| Dec 31, 2024 | -234.51 Mn |
| Sep 30, 2024 | -224.38 Mn |
| Jun 30, 2024 | -19.64 Mn |
| Dec 31, 2023 | 5.15 Bn |
| Sep 30, 2023 | -241.41 Mn |
| Jun 30, 2023 | -326.09 Mn |
| Dec 31, 2022 | -382.08 Mn |
| Sep 30, 2022 | -313.76 Mn |
| Jun 30, 2022 | -349.79 Mn |
| Dec 31, 2021 | -306.05 Mn |
| Sep 30, 2021 | -225.24 Mn |
| Jun 30, 2021 | -100.99 Mn |
| Dec 31, 2020 | -275.82 Mn |
| Sep 30, 2020 | -52.79 Mn |
| Jun 30, 2020 | -6.76 Mn |